Intellia Therapeutics, Inc. (NTLA) Reports Q3 Loss, Misses Revenue Estimates

Intellia Therapeutics, Inc. (NTLA) came out with a quarterly loss of $0.92 per share versus the Zacks Consensus Estimate of a loss of$ 1.02. This compares to a loss of $1.34 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +9.80%. A quarter ago, it was expected that this company would post a loss of$ 1.03 per share when it actually produced a loss of $0.99, delivering a surprise of +3.88%.Over the last four quarters, the compan ...